ACHN News 11.75 08/27/2014 04:24:00 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Achillion Pharmaceuticals (ACHN) 11.75 $ACHN

Nasdaq stocks posting largest percentage increases
AP - Tue Aug 26, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks
AP - Tue Aug 26, 5:05PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
at The Street - Tue Aug 26, 11:10AM CDT
Achillion Pharmaceuticals (ACHN) touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target.

3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.

Critical Alerts For Achillion Pharmaceuticals, Intel, YY, JA Solar and Skullcandy Released By InvestorsObserver
PR Newswire - Tue Aug 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, INTC, YY, JASO and SKUL.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.

More Biotech Mergers: Roche to Acquire InterMune (ITMN) - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 25, 3:43PM CDT
Roche is looking to buy InterMune, sending shares of ITMN up over 35 percent on the day.

Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 25, 1:27PM CDT
Achillion Pharmaceuticals (ACHN) surged to a 52-week high of $11.15 in afternoon trading Monday after UBS tabbed the company as a possible takeover target.

Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.

The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).

Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.

Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.

New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.

ACHILLION PHARMA
at Investor's Business Daily - Tue Aug 19, 5:47PM CDT
ACHILLION PHARMA (ACHN) got a patent OK for ACH-3102, its hepatitis C treatment. Shares rose 2.8% after closing up 3.5%.

Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
at The Street - Tue Aug 19, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102.

Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
GlobeNewswire - Tue Aug 19, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.

Can The Uptrend Continue for Achillion (ACHN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 6:57AM CDT
Can The Uptrend Continue for Achillion (ACHN)?
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 155

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 122

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 0

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

Epson Robots Unveils Cutting-Edge Automation Tech at Expo

Updated Category News Views 360

Innovative Automation Solutions by Epson Robots Epson Robots is set to showcase its latest high-performance automation solutions at an upcoming major tradeshow. The focus will be on the exciting advancements in the SCARA and 6-Axis robots, which are recognized globally for their efficiency and precision in various industries. Exciting New Product Launches At the event,...

Continue Reading
Rexel Reports Fourth Quarter Growth Amid Market Challenges

Updated Category News Views 313

Rexel's Financial Performance Overview Rexel has released its fourth quarter (Q4) and full year (FY) financial results, showcasing strong performance amid challenging market conditions. The company's FY 2024 sales reached €19,285.1 million, reflecting a modest year-on-year increase of 0.7% on a reported basis. This growth narrative underscores Rexel's effective...

Continue Reading
Monster Beverage Sees Gains in 2025 First Quarter Results

Updated Category News Views 313

Monster Beverage's Impressive First Quarter Growth 2025 First Quarter Highlights The financial landscape for Monster Beverage Corporation (NASDAQ: MNST) revealed compelling growth in the first quarter of 2025. Gross profit as a percentage of net sales improved significantly, reaching 56.5 percent. The company reported an operating income increase of 5.1 percent, totaling...

Continue Reading
Transforming Metastatic HR+/HER2- Breast Cancer Care Innovations

Updated Category News Views 215

Transforming Treatment Strategies for Metastatic HR+/HER2- Breast Cancer In recent years, the landscape of metastatic HR+/HER2- breast cancer treatment has evolved dramatically. With innovative therapies coming to the forefront, patients now have access to a wider range of treatment options that aim to improve survival rates and quality of life. The rise of targeted...

Continue Reading
Oil Price Surge Driven by Manufacturing Growth in China

Updated Category News Views 193

Understanding the Recent Trends in Oil Prices Oil prices experienced an uptick recently, driven by promising signs from China's manufacturing sector. Reports reveal that China's factory activity demonstrated growth in December, marking it as a significant development in the global oil landscape. However, despite this positive news, oil prices are on a trajectory to finish...

Continue Reading